Circulating Tumor Cells (CTC) in Cancer

Last updated: March 10, 2025
Sponsor: University Hospital, Basel, Switzerland
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Treatment

Blood samples

Samples from tumor draining vessels

Clinical Study ID

NCT04520672
2020-00014; me19Vetter
  • Ages > 18
  • All Genders

Study Summary

This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult cancer patients

  • All patients with histology-based proved diagnosis of cancer, all stages andsubtypes can be included. Precancerous lesions cannot be included.

  • All patients with the diagnosis of a solid tumor including adenocarcinoma, squamouscell carcinoma, neuroendocrine carcinoma, sarcoma

  • Written pathology report must be available.

  • Written informed consent.

Exclusion

Exclusion Criteria:

  • No written informed consent.

  • No proved diagnosis of malignancy by pathology report.

  • Patients with the diagnosis of blood cancer

Study Design

Total Participants: 3000
Treatment Group(s): 2
Primary Treatment: Blood samples
Phase:
Study Start date:
October 01, 2020
Estimated Completion Date:
August 31, 2030

Connect with a study center

  • University Hospital Basel

    Basel, 4031
    Switzerland

    Active - Recruiting

  • Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland

    Liestal, 4410
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.